KRAS and cancer: Despite being in the dose escalation phase, CCT3833 achieved a progression-free survival (PFS) of >10 months, and we provide comprehensive analysis of the mechanism of action of CCT3833 in KRAS-mutant cancers to reveal how this patient and others could benefit from this agent.